Senzime Launches Predictive AI Technology for Neuromuscular Monitoring
Senzime AB has received FDA 510(k) clearance for its Next-Generation TetraGraph® neuromuscular monitoring system. The company has announced EMGINE™ Aurora, a software upgrade introducing predictive recovery algorithms and enhanced patient-specific intubation readiness assessments.
The technology is designed to support anaesthesia professionals in monitoring neuromuscular function and assessing patients' recovery following the administration of neuromuscular blocking drugs.
EMGINE Aurora uses machine-learning techniques trained on real-world neuromuscular monitoring data collected from hospitals and TetraGraph users worldwide.
Its predictive algorithms estimate whether a patient is likely to achieve spontaneous neuromuscular recovery within a specified future period. This information can help clinicians plan recovery and make more informed decisions about reversal medication.
The software also introduces patient-specific intubation readiness indicators, moving beyond fixed time intervals after drug administration. Intelligent alerts and clinical guidance support individualised neuromuscular management throughout surgical procedures.
Senzime is also introducing TetraAnalytics 2.0, a cloud-based analytics platform enhanced with AI assistance. It is designed to help healthcare organisations identify variations in clinical practice, assess improvement opportunities and support quality-improvement initiatives.